Biogen Inc.
BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for thā¦ read more
Healthcare
Drug ManufacturersāGeneral
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$202.95
Price-2.40%
-$4.98
1Y
Price
Market Cap
$29.987b
Large
Price/Earnings 3y Avg5y Avg
12.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+22.3%
EBITDA Margin+12.9%
Net Profit Margin+28.1%
Free Cash Flow Margin+22.3%
EBITDA Margin+12.9%
Net Profit Margin+28.1%
Free Cash Flow MarginRevenue
$9.948b
+0.5%
1y CAGR+0.1%
3y CAGR-0.8%
5y CAGREarnings
$835.089m
+6.1%
1y CAGR+8.6%
3y CAGR-9.0%
5y CAGREPS
$5.65
+5.8%
1y CAGR+8.4%
3y CAGR-9.2%
5y CAGRBook Value
$18.848b
$32.087b
Assets$13.239b
Liabilities$8.355b
DebtDebt to Assets
26.0%
2.4x
Debt to EBITDAFree Cash Flow
$2.969b
+27.9%
1y CAGR+37.7%
3y CAGR+30.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company